SlideShare une entreprise Scribd logo
1  sur  12
TSE/BSE EVALUATION
PRESENTED BY:
Sridhar S
Pharmaceutical regulatory
affairs
JSSCP, Mysuru
PRESENTED TO:
Dr. Balamuralidara V
Asst. Professor
Dept. of Pharmaceutics
JSSCP, Mysuru
What is TSE
 TSE – Transmissible Spongiform Encephalopathy – In general, it
is a disease. A group of rare degenerative brain disorders
characterized by tiny holes that give the brain a "spongy"
appearance.
 It is a rare disease occurs in Humans and Vertebrate animals
(Vertebrate = Animals having backbone)
 TSE = A disease capable of being transmitted by infection and
gives the appearance of sponge like tiny holes in the brain.
There are many types of Human TSEs.
 The literal meaning of TSE is as below
Transmissible = Capable of being transmitted by infection
Spongiform = Sponge like
Encephalopathy = Brain Disease
What is BSE
 BSE – Bovine Spongiform Encephalopathy – It is a brain disease
that occurs in bovines; generally known as “Mad Cow Disease”
 It is a rare disease occurs in Vertebrate animals; for example,
cow/cattle.
 BSE = A disease capable of transmitted by infection and gives a
appearance of sponge like tiny holes in the brain of bovines.
 The literal meaning of BSE is as below
Bovine = Characteristic of or resembling cows or cattle.
Spongiform = Sponge like
Encephalopathy = Brain Disease
Causative Agent
 The causative agent is NOT a bacterium or a virus or a fungus or
any plant(s). It is a protein called as Prion, usually present in
the body cells of Human and Animals.
 The structure of the prion protein is given below
Prion have two forms as said below.
Prion = proteinaceous infectious particle, named as Prion Proteins
 Normal Form-A harmless protein found in the body's cells which
is unfolded in structure which does not cause TSE
 Abnormal Form-The protein which is in folded structure and can
cause TSE
• Both normal and abnormal prion are identical except the
folding in the structure of abnormal proteins. The accumulation
of an abnormal isoform of the prion protein in the Central
Nervous System causes the diseases. Creutzfeldt-Jakob disease
in its sporadic form is the most frequent type of human TSE
• After the name of the causative agent the disease is also named
as prion diseases.
DEVELOPMENT OF TSE/BSE
Spontaneous
development
of folded
protein in
sheep/goat
(by mutation)
Consumption
of meat
powder by
cattle/Bovine
to increase
the milk
productivity
Use of animal derived
products in
pharmaceuticals
Use of animal derived
products in
pharmaceuticals
Development of TSE
in Human
RISK of TSE/BSE in Pharmaceuticals
 There is a possible risk of contamination of infected animal
derived products in the pharmaceutical finished dosage form
for human consumption leads to transmission of TSE/BSE to
human beings.
 In some cases, the Pharmaceutical preparations like Finished
Dosage Forms, Active Pharmaceutical Ingredients and their
Starting Materials, and Primary Packaging Materials involves the
use of products/materials derived from animals. For example,
use of proteins, enzymes, amino acids from animals used in the
manufacturing of API and API starting materials.
 The primary packaging materials like gelatins capsules derived
from the fat of animals also increases the possibilities of
transmission of TSE/BSE.
 There is a high risk in the case of biotechnological products like
serums, blood products and vaccines where the source material is
derived from animals and animal derived products.
 There is also a possible risk of TSE/BSE through the
equipments/utilities where in biologically-derived products and/or
products of animal origin is handled. For example, Culture media used
in reactors for media fill studies.
 Ideally, the use of such animal derived product/material should be
avoided in the pharmaceutical preparation. However, during
unavoidable circumstances, the use of such animal derived products is
accepted, provided that the manufacturing process and procedures
complies to the applicable regulations set by WHO, European
Commission and USFDA.
Regulation
 Regulation (EC) No 999/2001 of the European Parliament and of
the Council of 22 May 2001 laying down rules for the
prevention, control and eradication of certain transmissible
spongiform encephalopathies
 The following guidance and regulatory compliance activities are
available at present:
• WHO Fact Sheet & Guidelines
• USFDA guidelines
• EU Guidelines
• General Monograph in European Pharmacopeia
• Certificate of Suitability for TSE/BSE by EDQM
• Canadian Guidelines
http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02001R0999-20150805
Inspections, Controls & Registration
 The Directorate General for Health and Food Safety of the
European Commission carries out audits in the Member States
to verify the correct implementation, enforcement and control
of EU legislation by the competent national authorities
 TSEs are laid down in Annex IX to the TSE Regulation, status of
third countries or regions thereof, as laid down in Commission
Decision 2007/453/EC.
Reference
 http://ec.europa.eu/food/safety/biosafety/food_borne_diseases/tse_bse_en
 http://www.insightcgmp.com/wp-content/uploads/2015/11/tse-bse-risk-
regulations.pdf
 http://eur-lex.europa.eu/legalcontent/EN/TXT/?uri=CELEX:02001R0999-
20150805
 http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/genera
l_content_000096.jsp&mid=WC0b01ac05800265d1
 http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listi
ng/document_listing_000138.jsp&mid=WC0b01ac05800265d2
 http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/genera
l_content_000533.jsp&mid=WC0b01ac05805716fa
 http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listi
ng/document_listing_000137.jsp&mid=WC0b01ac05800267b7
Any Question???????

Contenu connexe

Tendances

Marketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionMarketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionDoninder Hooda
 
Regulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologicsRegulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologicsNimmiRoy
 
REGULATORY CONSIDERATIONS IN JAPAN.pptx
REGULATORY CONSIDERATIONS IN JAPAN.pptxREGULATORY CONSIDERATIONS IN JAPAN.pptx
REGULATORY CONSIDERATIONS IN JAPAN.pptxAartiVats5
 
Medical Device Regulatory Approval
Medical Device Regulatory ApprovalMedical Device Regulatory Approval
Medical Device Regulatory Approvalruyang89
 
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA sandeep bansal
 
Clinical investigation and evaluation of medical devices and ivd.pptx
Clinical investigation and evaluation of medical devices and ivd.pptxClinical investigation and evaluation of medical devices and ivd.pptx
Clinical investigation and evaluation of medical devices and ivd.pptxreechashah2
 
Quality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in IndiaQuality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in IndiaS S N D Balakrishna Ch
 
20210413 nvfg acs iso14155 13_apr2021
20210413 nvfg acs iso14155 13_apr202120210413 nvfg acs iso14155 13_apr2021
20210413 nvfg acs iso14155 13_apr2021Annet Visscher
 
Drug approval process in japan
Drug approval process in japanDrug approval process in japan
Drug approval process in japanManish kumar
 
Prior Approval Supplements (PAS)
Prior Approval Supplements (PAS)Prior Approval Supplements (PAS)
Prior Approval Supplements (PAS)Nirma University
 
Abriviated new drug application 505(j) filling
Abriviated new drug application 505(j) fillingAbriviated new drug application 505(j) filling
Abriviated new drug application 505(j) fillingshahnawazQuadir
 
Who prequalification program
Who prequalification programWho prequalification program
Who prequalification programshweta more
 
Usa and canada ppt final ranju hod augst
Usa and canada ppt final ranju hod augstUsa and canada ppt final ranju hod augst
Usa and canada ppt final ranju hod augstRanjiniDM
 
European_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptxEuropean_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptxNikhilBorade5
 
labelling requirements and label claims for dietary supplements in USA
labelling requirements and label claims for dietary supplements in USAlabelling requirements and label claims for dietary supplements in USA
labelling requirements and label claims for dietary supplements in USAnavyasribandaru
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Aakashdeep Raval
 
GOOD AUTOMATED LABORATORY PRACTICE
GOOD AUTOMATED LABORATORY PRACTICEGOOD AUTOMATED LABORATORY PRACTICE
GOOD AUTOMATED LABORATORY PRACTICEjagrutivasava
 
Combination Products, Orphan Drugs and OTC Drugs
Combination Products, Orphan Drugs and OTC DrugsCombination Products, Orphan Drugs and OTC Drugs
Combination Products, Orphan Drugs and OTC DrugsMichael Swit
 
Risk Based Classification of Medical Devices and grouping
Risk Based Classification of Medical Devices and groupingRisk Based Classification of Medical Devices and grouping
Risk Based Classification of Medical Devices and groupingPaulyne Wairimu
 

Tendances (20)

Marketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionMarketing Authorization Procedure in European Union
Marketing Authorization Procedure in European Union
 
Regulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologicsRegulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologics
 
REGULATORY CONSIDERATIONS IN JAPAN.pptx
REGULATORY CONSIDERATIONS IN JAPAN.pptxREGULATORY CONSIDERATIONS IN JAPAN.pptx
REGULATORY CONSIDERATIONS IN JAPAN.pptx
 
Medical Device Regulatory Approval
Medical Device Regulatory ApprovalMedical Device Regulatory Approval
Medical Device Regulatory Approval
 
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
ACTIVE SUBSTANCE MSTER FILE (ASMF) eMA
 
Clinical investigation and evaluation of medical devices and ivd.pptx
Clinical investigation and evaluation of medical devices and ivd.pptxClinical investigation and evaluation of medical devices and ivd.pptx
Clinical investigation and evaluation of medical devices and ivd.pptx
 
Quality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in IndiaQuality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in India
 
20210413 nvfg acs iso14155 13_apr2021
20210413 nvfg acs iso14155 13_apr202120210413 nvfg acs iso14155 13_apr2021
20210413 nvfg acs iso14155 13_apr2021
 
Drug approval process in japan
Drug approval process in japanDrug approval process in japan
Drug approval process in japan
 
Prior Approval Supplements (PAS)
Prior Approval Supplements (PAS)Prior Approval Supplements (PAS)
Prior Approval Supplements (PAS)
 
Abriviated new drug application 505(j) filling
Abriviated new drug application 505(j) fillingAbriviated new drug application 505(j) filling
Abriviated new drug application 505(j) filling
 
Who prequalification program
Who prequalification programWho prequalification program
Who prequalification program
 
GHTF
GHTFGHTF
GHTF
 
Usa and canada ppt final ranju hod augst
Usa and canada ppt final ranju hod augstUsa and canada ppt final ranju hod augst
Usa and canada ppt final ranju hod augst
 
European_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptxEuropean_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptx
 
labelling requirements and label claims for dietary supplements in USA
labelling requirements and label claims for dietary supplements in USAlabelling requirements and label claims for dietary supplements in USA
labelling requirements and label claims for dietary supplements in USA
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.
 
GOOD AUTOMATED LABORATORY PRACTICE
GOOD AUTOMATED LABORATORY PRACTICEGOOD AUTOMATED LABORATORY PRACTICE
GOOD AUTOMATED LABORATORY PRACTICE
 
Combination Products, Orphan Drugs and OTC Drugs
Combination Products, Orphan Drugs and OTC DrugsCombination Products, Orphan Drugs and OTC Drugs
Combination Products, Orphan Drugs and OTC Drugs
 
Risk Based Classification of Medical Devices and grouping
Risk Based Classification of Medical Devices and groupingRisk Based Classification of Medical Devices and grouping
Risk Based Classification of Medical Devices and grouping
 

Similaire à TSE/BSE Evaluation

Prions ppt SBC 450.ppt
Prions ppt SBC 450.pptPrions ppt SBC 450.ppt
Prions ppt SBC 450.pptKimEliakim1
 
Do you know whats in the Swine Flu vaccine?
Do you know whats in the Swine Flu vaccine?Do you know whats in the Swine Flu vaccine?
Do you know whats in the Swine Flu vaccine?Crystal(Nada) Mitchell
 
Spongiform Encephalopathy's
Spongiform Encephalopathy'sSpongiform Encephalopathy's
Spongiform Encephalopathy'sAshish Deshpande
 
Vaccinating Your Horse (Marteniuk)
Vaccinating Your Horse (Marteniuk)Vaccinating Your Horse (Marteniuk)
Vaccinating Your Horse (Marteniuk)Gwyn Shelle
 
Vincent m. material (case study and ncp toxoplasmosis)
Vincent m. material (case study and ncp   toxoplasmosis)Vincent m. material (case study and ncp   toxoplasmosis)
Vincent m. material (case study and ncp toxoplasmosis)Vincent Material
 
Bovine spongiform encephalopathy by bishajit
Bovine spongiform encephalopathy by bishajitBovine spongiform encephalopathy by bishajit
Bovine spongiform encephalopathy by bishajitPrimeasia University
 
Finalprojectmadcow v cjd amaliamartinez
Finalprojectmadcow v cjd amaliamartinezFinalprojectmadcow v cjd amaliamartinez
Finalprojectmadcow v cjd amaliamartinezammmalia
 
Prions and it’s important diseases in veterinary field.
Prions and it’s important diseases in veterinary field.Prions and it’s important diseases in veterinary field.
Prions and it’s important diseases in veterinary field.Sameer Sankhe
 
Presentation 6 pryon diseases
Presentation 6 pryon diseasesPresentation 6 pryon diseases
Presentation 6 pryon diseasesbatsuuri nantsag
 
ANNUAHREE's presentation.pptx
ANNUAHREE's presentation.pptxANNUAHREE's presentation.pptx
ANNUAHREE's presentation.pptxannushree9
 
Bovine spongiform encephalopathy
Bovine spongiform encephalopathyBovine spongiform encephalopathy
Bovine spongiform encephalopathyRafat F Chowdhury
 

Similaire à TSE/BSE Evaluation (20)

Prions ppt SBC 450.ppt
Prions ppt SBC 450.pptPrions ppt SBC 450.ppt
Prions ppt SBC 450.ppt
 
Congenital anomalies
Congenital anomalies  Congenital anomalies
Congenital anomalies
 
Phenylketonuria
PhenylketonuriaPhenylketonuria
Phenylketonuria
 
Do you know whats in the Swine Flu vaccine?
Do you know whats in the Swine Flu vaccine?Do you know whats in the Swine Flu vaccine?
Do you know whats in the Swine Flu vaccine?
 
Spongiform Encephalopathy's
Spongiform Encephalopathy'sSpongiform Encephalopathy's
Spongiform Encephalopathy's
 
Brucella and mycoplasma
Brucella and mycoplasmaBrucella and mycoplasma
Brucella and mycoplasma
 
Brucellosis
BrucellosisBrucellosis
Brucellosis
 
Vaccinating Your Horse (Marteniuk)
Vaccinating Your Horse (Marteniuk)Vaccinating Your Horse (Marteniuk)
Vaccinating Your Horse (Marteniuk)
 
Vincent m. material (case study and ncp toxoplasmosis)
Vincent m. material (case study and ncp   toxoplasmosis)Vincent m. material (case study and ncp   toxoplasmosis)
Vincent m. material (case study and ncp toxoplasmosis)
 
Bovine spongiform encephalopathy by bishajit
Bovine spongiform encephalopathy by bishajitBovine spongiform encephalopathy by bishajit
Bovine spongiform encephalopathy by bishajit
 
Finalprojectmadcow v cjd amaliamartinez
Finalprojectmadcow v cjd amaliamartinezFinalprojectmadcow v cjd amaliamartinez
Finalprojectmadcow v cjd amaliamartinez
 
Polio
PolioPolio
Polio
 
Creutzfeldt-Jacob Disease
Creutzfeldt-Jacob DiseaseCreutzfeldt-Jacob Disease
Creutzfeldt-Jacob Disease
 
Poliomyelitis
PoliomyelitisPoliomyelitis
Poliomyelitis
 
Prions and it’s important diseases in veterinary field.
Prions and it’s important diseases in veterinary field.Prions and it’s important diseases in veterinary field.
Prions and it’s important diseases in veterinary field.
 
Presentation 6 pryon diseases
Presentation 6 pryon diseasesPresentation 6 pryon diseases
Presentation 6 pryon diseases
 
ANNUAHREE's presentation.pptx
ANNUAHREE's presentation.pptxANNUAHREE's presentation.pptx
ANNUAHREE's presentation.pptx
 
Prion disease
Prion diseasePrion disease
Prion disease
 
Bovine spongiform encephalopathy
Bovine spongiform encephalopathyBovine spongiform encephalopathy
Bovine spongiform encephalopathy
 
عرض شرح انواع السموم التي تنتجها الفطريات.pptx
عرض شرح انواع السموم التي تنتجها الفطريات.pptxعرض شرح انواع السموم التي تنتجها الفطريات.pptx
عرض شرح انواع السموم التي تنتجها الفطريات.pptx
 

Dernier

Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991RKavithamani
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxpboyjonauth
 
The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13Steve Thomason
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdfQucHHunhnh
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdfSoniaTolstoy
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpinRaunakKeshri1
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxheathfieldcps1
 
mini mental status format.docx
mini    mental       status     format.docxmini    mental       status     format.docx
mini mental status format.docxPoojaSen20
 
Hybridoma Technology ( Production , Purification , and Application )
Hybridoma Technology  ( Production , Purification , and Application  ) Hybridoma Technology  ( Production , Purification , and Application  )
Hybridoma Technology ( Production , Purification , and Application ) Sakshi Ghasle
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxSayali Powar
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingTechSoup
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityGeoBlogs
 
CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxGaneshChakor2
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...Marc Dusseiller Dusjagr
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfciinovamais
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introductionMaksud Ahmed
 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfsanyamsingh5019
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxiammrhaywood
 

Dernier (20)

Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptx
 
The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpin
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
mini mental status format.docx
mini    mental       status     format.docxmini    mental       status     format.docx
mini mental status format.docx
 
Hybridoma Technology ( Production , Purification , and Application )
Hybridoma Technology  ( Production , Purification , and Application  ) Hybridoma Technology  ( Production , Purification , and Application  )
Hybridoma Technology ( Production , Purification , and Application )
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy Consulting
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activity
 
Mattingly "AI & Prompt Design: The Basics of Prompt Design"
Mattingly "AI & Prompt Design: The Basics of Prompt Design"Mattingly "AI & Prompt Design: The Basics of Prompt Design"
Mattingly "AI & Prompt Design: The Basics of Prompt Design"
 
CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptx
 
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdfTataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdf
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
 

TSE/BSE Evaluation

  • 1. TSE/BSE EVALUATION PRESENTED BY: Sridhar S Pharmaceutical regulatory affairs JSSCP, Mysuru PRESENTED TO: Dr. Balamuralidara V Asst. Professor Dept. of Pharmaceutics JSSCP, Mysuru
  • 2. What is TSE  TSE – Transmissible Spongiform Encephalopathy – In general, it is a disease. A group of rare degenerative brain disorders characterized by tiny holes that give the brain a "spongy" appearance.  It is a rare disease occurs in Humans and Vertebrate animals (Vertebrate = Animals having backbone)  TSE = A disease capable of being transmitted by infection and gives the appearance of sponge like tiny holes in the brain. There are many types of Human TSEs.  The literal meaning of TSE is as below Transmissible = Capable of being transmitted by infection Spongiform = Sponge like Encephalopathy = Brain Disease
  • 3. What is BSE  BSE – Bovine Spongiform Encephalopathy – It is a brain disease that occurs in bovines; generally known as “Mad Cow Disease”  It is a rare disease occurs in Vertebrate animals; for example, cow/cattle.  BSE = A disease capable of transmitted by infection and gives a appearance of sponge like tiny holes in the brain of bovines.  The literal meaning of BSE is as below Bovine = Characteristic of or resembling cows or cattle. Spongiform = Sponge like Encephalopathy = Brain Disease
  • 4. Causative Agent  The causative agent is NOT a bacterium or a virus or a fungus or any plant(s). It is a protein called as Prion, usually present in the body cells of Human and Animals.  The structure of the prion protein is given below
  • 5. Prion have two forms as said below. Prion = proteinaceous infectious particle, named as Prion Proteins  Normal Form-A harmless protein found in the body's cells which is unfolded in structure which does not cause TSE  Abnormal Form-The protein which is in folded structure and can cause TSE • Both normal and abnormal prion are identical except the folding in the structure of abnormal proteins. The accumulation of an abnormal isoform of the prion protein in the Central Nervous System causes the diseases. Creutzfeldt-Jakob disease in its sporadic form is the most frequent type of human TSE • After the name of the causative agent the disease is also named as prion diseases.
  • 6. DEVELOPMENT OF TSE/BSE Spontaneous development of folded protein in sheep/goat (by mutation) Consumption of meat powder by cattle/Bovine to increase the milk productivity Use of animal derived products in pharmaceuticals Use of animal derived products in pharmaceuticals Development of TSE in Human
  • 7. RISK of TSE/BSE in Pharmaceuticals  There is a possible risk of contamination of infected animal derived products in the pharmaceutical finished dosage form for human consumption leads to transmission of TSE/BSE to human beings.  In some cases, the Pharmaceutical preparations like Finished Dosage Forms, Active Pharmaceutical Ingredients and their Starting Materials, and Primary Packaging Materials involves the use of products/materials derived from animals. For example, use of proteins, enzymes, amino acids from animals used in the manufacturing of API and API starting materials.  The primary packaging materials like gelatins capsules derived from the fat of animals also increases the possibilities of transmission of TSE/BSE.
  • 8.  There is a high risk in the case of biotechnological products like serums, blood products and vaccines where the source material is derived from animals and animal derived products.  There is also a possible risk of TSE/BSE through the equipments/utilities where in biologically-derived products and/or products of animal origin is handled. For example, Culture media used in reactors for media fill studies.  Ideally, the use of such animal derived product/material should be avoided in the pharmaceutical preparation. However, during unavoidable circumstances, the use of such animal derived products is accepted, provided that the manufacturing process and procedures complies to the applicable regulations set by WHO, European Commission and USFDA.
  • 9. Regulation  Regulation (EC) No 999/2001 of the European Parliament and of the Council of 22 May 2001 laying down rules for the prevention, control and eradication of certain transmissible spongiform encephalopathies  The following guidance and regulatory compliance activities are available at present: • WHO Fact Sheet & Guidelines • USFDA guidelines • EU Guidelines • General Monograph in European Pharmacopeia • Certificate of Suitability for TSE/BSE by EDQM • Canadian Guidelines http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02001R0999-20150805
  • 10. Inspections, Controls & Registration  The Directorate General for Health and Food Safety of the European Commission carries out audits in the Member States to verify the correct implementation, enforcement and control of EU legislation by the competent national authorities  TSEs are laid down in Annex IX to the TSE Regulation, status of third countries or regions thereof, as laid down in Commission Decision 2007/453/EC.
  • 11. Reference  http://ec.europa.eu/food/safety/biosafety/food_borne_diseases/tse_bse_en  http://www.insightcgmp.com/wp-content/uploads/2015/11/tse-bse-risk- regulations.pdf  http://eur-lex.europa.eu/legalcontent/EN/TXT/?uri=CELEX:02001R0999- 20150805  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/genera l_content_000096.jsp&mid=WC0b01ac05800265d1  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listi ng/document_listing_000138.jsp&mid=WC0b01ac05800265d2  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/genera l_content_000533.jsp&mid=WC0b01ac05805716fa  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listi ng/document_listing_000137.jsp&mid=WC0b01ac05800267b7